Wall Street PR

Company

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Why Pfizer Stock Blasted More Than 6% Higher Today

Date:

A double beat on earnings, plus raised bottom-line guidance, made the company a hot item on Hump Day.

Pfizer (PFE 6.09%) stock got a very effective shot in the arm on Wednesday. This was supplied by its latest earnings release, which saw the storied pharmaceutical company notch double beats on analyst estimates and provide encouraging guidance. The company’s share price ended the day more than 6% higher, in contrast to the 0.3% slump of the S&P 500 index.

The Covid effect not as damaging as feared

For its first quarter, Pfizer reported before market open, the pharmaceutical giant took in just under $14.9 billion in revenue. While this was 20% below its first-quarter 2023 revenue, it wasn’t unexpected — the company continues to see a notable fall-off in sales of its Covid products (namely the Comirnaty vaccine and Paxlovid, a drug). Removing such goods from the equation, Pfizer would have enjoyed 11% year-over-year revenue growth.

That dynamic also affected profitability. Non-GAAP (adjusted) net income saw a steeper fall, tumbling by 34% to $4.7 billion ($0.82 per share).

At first glance, those drops were seriously bad news. However, analysts were expecting far worse. On average, they were estimating that Pfizer’s revenue would total barely over $14 billion, and adjusted net income would be a mere $0.33 per share.

In the earnings release, the company quoted its CEO Albert Bourla as attributing the better-than-expected performance to “increased revenue from several of our recent commercial launches and acquired products, as well as robust year-over-year growth for several key in-line brands, namely the Vyndaqel family, Eliquis, and the Prevnar family.”

Pfizer also did well with oncology drugs such as Ibrance and Xtandi.

Full-year profitability guidance raised

Pfizer’s double beat on trailing results was compounded by a raise in profitability guidance. The company now believes its full-year adjusted net income will land at $2.15 to $2.35 per share, giving it a real shot at exceeding the collective $2.21 estimate from analysts. It left its revenue forecast unchanged; this stands at $58.5 billion to $61.5 billion, with the average prognosticator estimate at $60 billion.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.

Go Source

Chart

SignUp For Breaking Alerts

New Graphic

We respect your email privacy

Share post:

Popular

More like this
Related

Trump Exhibits Patience on Trade, But Not on Immigration: Jan. 21, 2025

An easing of Trump’s tough tariff talk is allowing...

The Honeymoon Continues

Your Privacy When you visit any website it may use...

5,000 Earnings Expiration Puts Trade in Element Solutions Inc (Symbol: ESI)

Your Privacy When you visit any website it may use...

‘Tis the Seasonal Volatility

Dmitry Pargamanik and Will McBride, the cofounders of Market...